Eli Lilly and Company (NYSE:LLY) Given New $1,200.00 Price Target at Wells Fargo & Company

Eli Lilly and Company (NYSE:LLY) had its target price boosted by investment analysts at Wells Fargo & Company from $1,100.00 to $1,200.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 20.65% from the company’s current price.

LLY has been the topic of a number of other research reports. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. BMO Capital Markets set a $1,200.00 target price on Eli Lilly and Company in a research report on Thursday, December 4th. Sanford C. Bernstein upped their price target on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a report on Monday, November 24th. Finally, Guggenheim restated a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,109.24.

Eli Lilly and Company Stock Up 1.3%

Shares of NYSE:LLY traded up $12.39 during trading on Wednesday, reaching $994.61. 2,095,774 shares of the stock were exchanged, compared to its average volume of 4,027,309. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The stock has a fifty day moving average of $928.62 and a two-hundred day moving average of $814.21. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a market cap of $940.29 billion, a price-to-earnings ratio of 48.71, a price-to-earnings-growth ratio of 1.11 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter last year, the firm posted $1.18 EPS. Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Large investors have recently added to or reduced their stakes in the company. Lazard Freres Gestion S.A.S. boosted its holdings in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK lifted its position in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares in the last quarter. Family CFO Inc acquired a new position in Eli Lilly and Company during the second quarter worth $54,000. Finally, Duquesne Family Office LLC grew its holdings in Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.